San Diego-dependent Viking Therapeutics marked by itself as a serious competitor within the weight loss drug sector in February just after revealing promising details from the mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection and in March the company un